26/01/2010
print this
article | 
email article to a friend
Novo Nordisk has announced that it is about to commence clinical trials on an oral form of Victoza, a glucagon-like peptide. Victoza has been approved for the treatment of type 2 diabetes but its license is currently limited to an injectable form.Full article
Link:
http://www.bioscinews.co.uk/article.aspx?articleid=1883
BioSci Contact:
Jo Thurston
News Source:
Categories:
Endocrinology
|